RESUMEN
The awarding of the gold medal from the Catalan Society of Transplantation to the organizers of the Banff Transplant Pathology meetings is an opportunity to acknowledge gratitude to all the people who have helped make these meetings a success over the past 26 years. Other large organizations have given up consensus conferences, but the Banff consensus process is thriving. It is unusual for any organization to have the same leadership for 26 years. It has only worked for the Banff meetings because the leadership was flexible and able to change with the times. People have often talked about the "special Banff spirit." This year's meeting gave us the opportunity to examine this spirit in detail by analyzing how the meeting consensus sessions and social events functioned. The meeting has never used expert facilitators, but instead has employed experts within the transplant pathology community to moderate discussions. The size of the working sessions is important; they have usually been less than 150 people, which is within "Dunbar's number," meaning that in gatherings of that size one can have empathetic feeling for all the people there. In larger gatherings one loses that "we are all in this together" feeling and people begin thinking "us" versus "them" thoughts. For "unknown" young people the ability to easily talk to well-known leaders in the field is rewarding and keeps them coming back for more time after time. Images of the social events do not suggest any sort of hierarchy; everyone interacts with everyone else.
Asunto(s)
Distinciones y Premios , Trasplante , Canadá , Congresos como Asunto , Humanos , Sociedades Médicas , Estados UnidosRESUMEN
The 12th Banff Conference on Allograft Pathology was held in Comandatuba, Brazil, from August 19-23, 2013, and was preceded by a 2-day Latin American Symposium on Transplant Immunobiology and Immunopathology. The meeting was highlighted by the presentation of the findings of several working groups formed at the 2009 and 2011 Banff meetings to: (1) establish consensus criteria for diagnosing antibody-mediated rejection (ABMR) in the presence and absence of detectable C4d deposition; (2) develop consensus definitions and thresholds for glomerulitis (g score) and chronic glomerulopathy (cg score), associated with improved inter-observer agreement and correlation with clinical, molecular and serological data; (3) determine whether isolated lesions of intimal arteritis ("isolated v") represent acute rejection similar to intimal arteritis in the presence of tubulointerstitial inflammation; (4) compare different methodologies for evaluating interstitial fibrosis and for performing/evaluating implantation biopsies of renal allografts with regard to reproducibility and prediction of subsequent graft function; and (5) define clinically and prognostically significant morphologic criteria for subclassifying polyoma virus nephropathy. The key outcome of the 2013 conference is defining criteria for diagnosis of C4d-negative ABMR and respective modification of the Banff classification. In addition, three new Banff Working Groups were initiated.
Asunto(s)
Arteritis/etiología , Complemento C4b/metabolismo , Rechazo de Injerto/etiología , Isoanticuerpos/inmunología , Trasplante de Órganos/efectos adversos , Fragmentos de Péptidos/metabolismo , Arteritis/metabolismo , Rechazo de Injerto/metabolismo , Humanos , Informe de InvestigaciónRESUMEN
The 11th Banff meeting was held in Paris, France, from June 5 to 10, 2011, with a focus on refining diagnostic criteria for antibody-mediated rejection (ABMR). The major outcome was the acknowledgment of C4d-negative ABMR in kidney transplants. Diagnostic criteria for ABMR have also been revisited in other types of transplants. It was recognized that ABMR is associated with heterogeneous phenotypes even within the same type of transplant. This highlights the necessity of further refining the respective diagnostic criteria, and is of particular significance for the design of randomized clinical trials. A reliable phenotyping will allow for definition of robust end-points. To address this unmet need and to allow for an evidence-based refinement of the Banff classification, Banff Working Groups presented multicenter data regarding the reproducibility of features relevant to the diagnosis of ABMR. However, the consensus was that more data are necessary and further Banff Working Group activities were initiated. A new Banff working group was created to define diagnostic criteria for ABMR in kidneys independent of C4d. Results are expected to be presented at the 12th Banff meeting to be held in 2013 in Brazil. No change to the Banff classification occurred in 2011.
Asunto(s)
Complemento C4b/inmunología , Rechazo de Injerto/diagnóstico , Rechazo de Injerto/inmunología , Trasplante de Riñón/inmunología , Fragmentos de Péptidos/inmunología , Ensayos Clínicos como Asunto , Congresos como Asunto , Rechazo de Injerto/clasificación , Humanos , Proyectos de InvestigaciónRESUMEN
The first Banff proposal for the diagnosis of pancreas rejection (Am J Transplant 2008; 8: 237) dealt primarily with the diagnosis of acute T-cell-mediated rejection (ACMR), while only tentatively addressing issues pertaining to antibody-mediated rejection (AMR). This document presents comprehensive guidelines for the diagnosis of AMR, first proposed at the 10th Banff Conference on Allograft Pathology and refined by a broad-based multidisciplinary panel. Pancreatic AMR is best identified by a combination of serological and immunohistopathological findings consisting of (i) identification of circulating donor-specific antibodies, and histopathological data including (ii) morphological evidence of microvascular tissue injury and (iii) C4d staining in interacinar capillaries. Acute AMR is diagnosed conclusively if these three elements are present, whereas a diagnosis of suspicious for AMR is rendered if only two elements are identified. The identification of only one diagnostic element is not sufficient for the diagnosis of AMR but should prompt heightened clinical vigilance. AMR and ACMR may coexist, and should be recognized and graded independently. This proposal is based on our current knowledge of the pathogenesis of pancreas rejection and currently available tools for diagnosis. A systematized clinicopathological approach to AMR is essential for the development and assessment of much needed therapeutic interventions.
Asunto(s)
Autoanticuerpos/inmunología , Rechazo de Injerto/diagnóstico , Trasplante de Páncreas/inmunología , Guías de Práctica Clínica como Asunto , Rechazo de Injerto/inmunología , HumanosRESUMEN
Ritonavir therapy is not generally considered nephrotoxic. We report a case of acute kidney injury secondary to ritonavir, with kidney biopsy demonstrating extensive acute tubular injury. This is the first report of a kidney biopsy and pathology in acute kidney injury associated with ritonavir. A review of published medical literature on the topic is also presented.
Asunto(s)
Lesión Renal Aguda/inducido químicamente , Infecciones por VIH/tratamiento farmacológico , Inhibidores de la Proteasa del VIH/efectos adversos , Riñón/efectos de los fármacos , Ritonavir/efectos adversos , Lesión Renal Aguda/patología , Terapia Antirretroviral Altamente Activa , Biomarcadores/sangre , Biopsia , Creatinina/sangre , Sustitución de Medicamentos , Humanos , Riñón/patología , Túbulos Renales/efectos de los fármacos , Túbulos Renales/patología , Masculino , Persona de Mediana Edad , Factores de TiempoRESUMEN
The 10th Banff Conference on Allograft Pathology was held in Banff, Canada from August 9 to 14, 2009. A total of 263 transplant clinicians, pathologists, surgeons, immunologists and researchers discussed several aspects of solid organ transplants with a special focus on antibody mediated graft injury. The willingness of the Banff process to adapt continuously in response to new research and improve potential weaknesses, led to the implementation of six working groups on the following areas: isolated v-lesion, fibrosis scoring, glomerular lesions, molecular pathology, polyomavirus nephropathy and quality assurance. Banff working groups will conduct multicenter trials to evaluate the clinical relevance, practical feasibility and reproducibility of potential changes to the Banff classification. There were also sessions on quality improvement in biopsy reading and utilization of virtual microscopy for maintaining competence in transplant biopsy interpretation. In addition, compelling molecular research data led to the discussion of incorporation of omics-technologies and discovery of new tissue markers with the goal of combining histopathology and molecular parameters within the Banff working classification in the near future.
Asunto(s)
Anticuerpos/química , Trasplante de Órganos/métodos , Biopsia , Canadá , Complemento C4b/metabolismo , Fibrosis/patología , Humanos , Enfermedades Renales/diagnóstico , Enfermedades Renales/patología , Enfermedades Renales/virología , Trasplante de Riñón , Estudios Multicéntricos como Asunto , Fragmentos de Péptidos/metabolismo , Fenotipo , Infecciones por Polyomavirus/diagnóstico , Control de CalidadRESUMEN
We reviewed 116 surveillance biopsies obtained approximately 1, 3, 6 and 12 months posttransplantation from 50 +XM live donor kidney transplant recipients to determine the frequency of subclinical cell-mediated rejection (CMR) and antibody-mediated rejection (AMR). Subclinical CMR was present in 39.7% of the biopsies at 1 month and >20% at all other time points. The presence of diffuse C4d on biopsies obtained at each time interval ranged from 20 to 30%. In every case, where histological and immunohistological findings were diagnostic for AMR, donor-specific antibody was found in the blood, challenging the long-held belief that low-level antibody could evade detection due to absorption on the graft. Among clinical factors, only recipient age was associated with subclinical CMR. Clinical factors associated with subclinical AMR were recipient age, positive cytotoxic crossmatch prior to desensitization and two mismatches of HLA DR 51, 52 and 53 alleles. Surveillance biopsies during the first year post-transplantation for these high-risk patients uncover clinically occult processes and phenotypes, which without intervention diminish allograft survival and function.
Asunto(s)
Rechazo de Injerto/epidemiología , Rechazo de Injerto/inmunología , Prueba de Histocompatibilidad/efectos adversos , Trasplante de Riñón/inmunología , Adulto , Alelos , Biopsia , Linfocitos T CD4-Positivos/inmunología , Linfocitos T CD4-Positivos/patología , Creatinina/sangre , Estudios Transversales , Femenino , Estudios de Seguimiento , Antígenos HLA-DR/genética , Antígenos HLA-DR/inmunología , Cadenas HLA-DRB4 , Cadenas HLA-DRB5 , Humanos , Incidencia , Riñón/patología , Riñón/fisiología , Masculino , Persona de Mediana Edad , Estudios RetrospectivosRESUMEN
Accurate diagnosis and grading of rejection and other pathological processes are of paramount importance to guide therapeutic interventions in patients with pancreas allograft dysfunction. A multi-disciplinary panel of pathologists, surgeons and nephrologists was convened for the purpose of developing a consensus document delineating the histopathological features for diagnosis and grading of rejection in pancreas transplant biopsies. Based on the available published data and the collective experience, criteria for the diagnosis of acute cell-mediated allograft rejection (ACMR) were established. Three severity grades (I/mild, II/moderate and III/severe) were defined based on lesions known to be more or less responsive to treatment and associated with better- or worse-graft outcomes, respectively. The features of chronic rejection/graft sclerosis were reassessed, and three histological stages were established. Tentative criteria for the diagnosis of antibody-mediated rejection were also characterized, in anticipation of future studies that ought to provide more information on this process. Criteria for needle core biopsy adequacy and guidelines for pathology reporting were also defined. The availability of a simple, reproducible, clinically relevant and internationally accepted schema for grading rejection should improve the level of diagnostic accuracy and facilitate communication between all parties involved in the care of pancreas transplant recipients.
Asunto(s)
Rechazo de Injerto/clasificación , Rechazo de Injerto/patología , Trasplante de Páncreas , Páncreas/patología , Trasplante Homólogo/patología , Biopsia , Rechazo de Injerto/diagnóstico , HumanosRESUMEN
The 9th Banff Conference on Allograft Pathology was held in La Coruna, Spain on June 23-29, 2007. A total of 235 pathologists, clinicians and scientists met to address unsolved issues in transplantation and adapt the Banff schema for renal allograft rejection in response to emerging data and technologies. The outcome of the consensus discussions on renal pathology is provided in this article. Major updates from the 2007 Banff Conference were: inclusion of peritubular capillaritis grading, C4d scoring, interpretation of C4d deposition without morphological evidence of active rejection, application of the Banff criteria to zero-time and protocol biopsies and introduction of a new scoring for total interstitial inflammation (ti-score). In addition, emerging research data led to the establishment of collaborative working groups addressing issues like isolated 'v' lesion and incorporation of omics-technologies, paving the way for future combination of graft biopsy and molecular parameters within the Banff process.
Asunto(s)
Trasplante de Riñón/patología , Biopsia , Ensayos Clínicos como Asunto , Complemento C4b/análisis , Rechazo de Injerto/patología , Rechazo de Injerto/prevención & control , Supervivencia de Injerto , Humanos , Inmunosupresores/uso terapéutico , Trasplante de Riñón/inmunología , Fragmentos de Péptidos/análisis , Trasplante HomólogoRESUMEN
We examined rejection outcome and graft survival in 58 adult patients with acute cellular rejection Banff type I (ARI) or II (ARII), within 1 year after transplantation, with or without CD20-positive infiltrates. Antibody-mediated rejection was not examined. Of the 74 allograft biopsies, performed from 1999 to 2001, 40 biopsies showed ARI and 34 biopsies showed ARII; 30% of all the biopsies showed CD20-positive clusters with more than 100 cells, 9% with more than 200 cells and 5% with more than 275 cells. Patients with B cell-rich (>100 or >200/HPF CD20-positive cells) and B cell-poor biopsies (<50 CD20-positive cells/HPF) were compared. Serum creatinine and eGFR of B cell-rich (CD20 > 100/HPF) and B cell-poor were not significantly different at rejection, or at 1, 3, 6 and 12 months, and during additional 3 years follow-up after rejection, although higher creatinine at 1 year was noted in the >200/HPF group. Graft survival was also not different between B cell-rich and B cell-poor groups (p = 0.8 for >100/HPF, p = 0.9 for >200/HPF CD20-positive cells). Our data do not support association of B cell-rich infiltrates in allograft biopsies and worse outcome in acute rejection type I or II, but do not exclude the possible contribution of B cells to allograft rejection.
Asunto(s)
Antígenos CD20/inmunología , Rechazo de Injerto/patología , Supervivencia de Injerto/inmunología , Trasplante de Riñón/inmunología , Enfermedad Aguda , Adulto , Anciano , Linfocitos B/inmunología , Linfocitos B/patología , Creatinina/sangre , Ensayo de Inmunoadsorción Enzimática , Femenino , Estudios de Seguimiento , Tasa de Filtración Glomerular , Rechazo de Injerto/sangre , Rechazo de Injerto/inmunología , Humanos , Masculino , Persona de Mediana Edad , Pronóstico , Estudios Retrospectivos , Índice de Severidad de la Enfermedad , Factores de TiempoRESUMEN
The 8th Banff Conference on Allograft Pathology was held in Edmonton, Canada, 15-21 July 2005. Major outcomes included the elimination of the non-specific term "chronic allograft nephropathy" (CAN) from the Banff classification for kidney allograft pathology, and the recognition of the entity of chronic antibody-mediated rejection. Participation of B cells in allograft rejection and genomics markers of rejection were also major subjects addressed by the conference.
Asunto(s)
Rechazo de Injerto/diagnóstico , Fallo Renal Crónico/diagnóstico , Trasplante de Riñón , Anticuerpos/inmunología , Linfocitos B/inmunología , Enfermedad Crónica , Diagnóstico Diferencial , Fibrosis , Marcadores Genéticos , Rechazo de Injerto/genética , Rechazo de Injerto/patología , Humanos , Riñón/inmunología , Riñón/patología , Fallo Renal Crónico/genética , Fallo Renal Crónico/patología , Trasplante de ÓrganosRESUMEN
Subclinical antibody-mediated rejection (AMR) has been described in renal allograft recipients with stable serum creatinine (SCr), however whether this leads to development of chronic allograft nephropathy (CAN) remains unknown. We retrospectively reviewed data from 83 patients who received HLA-incompatible renal allografts following desensitization to remove donor-specific antibodies (DSA). Ten patients had an allograft biopsy showing subclinical AMR [stable SCr, neutrophil margination in peritubular capillaries (PTC), diffuse PTC C4d, positive DSA] during the first year post-transplantation; 3 patients were treated with plasmapheresis and intravenous immunoglobulin. Three patients had a subsequent rise in SCr and an associated biopsy with AMR; 5 others showed diagnostic or possible subclinical AMR on a later protocol biopsy. One graft was lost, while remaining patients have normal or mildly elevated SCr 8-45 months post-transplantation. However, the mean increase in CAN score (cg + ci + ct + cv) from those biopsies showing subclinical AMR to follow-up biopsies 335 +/- 248 (SD) days later was significantly greater (3.5 +/- 2.5 versus 1.0 +/- 2.0, p = 0.01) than that in 24 recipients of HLA-incompatible grafts with no AMR over a similar interval (360 +/- 117 days), suggesting that subclinical AMR may contribute to development of CAN.
Asunto(s)
Anticuerpos/inmunología , Rechazo de Injerto/diagnóstico , Antígenos HLA-A/inmunología , Histocompatibilidad , Trasplante de Riñón , Insuficiencia Renal/diagnóstico , Adulto , Negro o Afroamericano , Anciano , Complemento C4b/análisis , Creatinina/sangre , Femenino , Rechazo de Injerto/inmunología , Humanos , Masculino , Persona de Mediana Edad , Fragmentos de Péptidos/análisis , Insuficiencia Renal/inmunología , Insuficiencia Renal/patología , Trasplante Homólogo , Población BlancaRESUMEN
A 1-day symposium on the application of protocol biopsies in renal transplantation was held in Boston, 21 July 2006. Representatives from centers with extensive experience in the use of protocol biopsies for routine patient care and research reported results on the pathological findings and their value in patient management. The consensus was that protocol biopsies, in experienced hands, are a safe and valuable means of detecting subclinical disease that can benefit from modification of therapy. Furthermore, molecular studies reveal evidence of activity or progression not readily appreciated by histological techniques. Wider application is expected in multicenter clinical trials to predict and validate outcomes. The principal barrier to wider use of protocol biopsies is knowledge of the benefits of intervention.
Asunto(s)
Biopsia/métodos , Rechazo de Injerto/diagnóstico , Trasplante de Riñón , Complicaciones Posoperatorias/diagnóstico , Biomarcadores/análisis , Ensayos Clínicos como Asunto , Rechazo de Injerto/etiología , Rechazo de Injerto/patología , Humanos , Atención al Paciente/métodos , Complicaciones Posoperatorias/etiología , Complicaciones Posoperatorias/patologíaRESUMEN
Biopsies of ABO-incompatible and positive crossmatch (HLA-incompatible) renal allografts were retrospectively examined to compare results of C4d and C3d staining, and the correlation between such staining and histologic findings suggestive of antibody-mediated rejection (AMR). A total of 75 biopsies (55 protocol, 17 for graft dysfunction, 3 for other indications) of 24 ABO-incompatible grafts and 244 biopsies (103 protocol, 129 for graft dysfunction, 12 for other indications) of 66 HLA-incompatible grafts were examined; all were stained for C4d and approximately 40% for C3d. In ABO-incompatible grafts, 80% of protocol biopsies and 59% performed for graft dysfunction showed C4d staining in peritubular capillaries (PTC); this staining was not correlated with neutrophil margination in PTC. In HLA-incompatible grafts, PTC C4d was present in 26% of protocol biopsies and 60% of biopsies for graft dysfunction; 92% of biopsies with >1+ (0-4+ scale), diffuse PTC C4d had > or =1+ margination and/or thrombotic microangiopathy (TMA), compared with 12% of C4d-negative biopsies. C3d was somewhat more predictive of margination than C4d in ABO-incompatible, but not HLA-incompatible, grafts. In summary, while PTC C4d deposition indicates probable AMR in biopsies of HLA-incompatible grafts, including protocol biopsies, there is no histologic evidence that C4d deposition is correlated with injury in most ABO-incompatible grafts.
Asunto(s)
Incompatibilidad de Grupos Sanguíneos/inmunología , Complemento C3d/metabolismo , Complemento C4/metabolismo , Antígenos HLA/inmunología , Enfermedades Renales/patología , Trasplante de Riñón/inmunología , Trasplante de Riñón/patología , Sistema del Grupo Sanguíneo ABO/inmunología , Sistema del Grupo Sanguíneo ABO/metabolismo , Anticuerpos/inmunología , Biopsia , Incompatibilidad de Grupos Sanguíneos/metabolismo , Rechazo de Injerto/inmunología , Enfermedades Renales/inmunología , Enfermedades Renales/metabolismo , Enfermedades Renales/cirugía , Trasplante Homólogo/inmunologíaRESUMEN
Molecular tools may prove useful for diagnosis, monitoring, and definition of basic mechanisms in transplantation. These techniques must be quantitative, reproducible and rapid, displaying known sensitivity and specificity. Powerful new techniques with "real-time" application, as briefly reviewed herein, are moving closer to clinical utility.
Asunto(s)
Técnicas Genéticas , Trasplante , Humanos , Reacción en Cadena de la Polimerasa/métodosRESUMEN
The pathological findings on renal allograft biopsy specimens are often complex. By carefully defining the morphological features of acute allograft rejection, the Banff schema provides an important tool for the differential diagnosis of acute allograft dysfunction. This article reviews the criteria for diagnosis of rejection, and its differentiation from other inflammatory infiltrates in renal allograft biopsy specimens.
Asunto(s)
Complicaciones Posoperatorias/diagnóstico , Trasplante Homólogo , Diagnóstico Diferencial , Rechazo de Injerto/diagnóstico , Humanos , Reproducibilidad de los ResultadosRESUMEN
Antibody-mediated rejection is increasingly recognized as a cause of acute and chronic rejection in kidney as well as other organ allografts. New diagnostic criteria have been drafted to diagnose this entity and enable timely therapy.
Asunto(s)
Rechazo de Injerto/inmunología , Isoanticuerpos/inmunología , Trasplante de Riñón/inmunología , Enfermedad Aguda , Enfermedad Crónica , HumanosRESUMEN
BACKGROUND: Acute transplant glomerulitis is a unique lesion in renal allografts, the prognostic significance of which is controversial. We conducted this retrospective cohort study to examine the independent prognostic significance of moderate-to-severe transplant glomerulitis in acute rejection. METHODS: Renal allograft survival for patients with acute rejection were studied, comparing one group with significant glomerulitis (G, n=28) with those with no glomerulitis (NG, n=35). Clinical, biopsy, and demographic data and renal graft survival were compared, and the association of G with graft failure was examined. RESULTS: In the G versus NG group, a greater percentage of patients were highly sensitized (peak panel reactive antibody value >80%; P=0.009), had had a previous renal transplant (40% vs. 11%; P=0.02), or had suffered from delayed graft function (P=0.03). The G group had a trend toward earlier rejection episodes (P=0.07), a significantly higher serum creatinine at the time of index biopsy (P=0.01), a higher prevalence of vascular rejection (P=0.02), and less improvement in mean reciprocal serum creatinine at 1-2 weeks after biopsy (P=0.02). Although there was a trend toward shorter allograft survival in the G group (P=0.09), the level of significance of which increased with adjustment for transplantation time period and the duration of the transplant-biopsy interval (P=0.06), the relative risk for graft loss was no longer significant when additionally adjusted for index biopsy Banff score (relative risk, 0.97; P=0.97). CONCLUSION: In this study, G was significantly more common in highly sensitized patients and was strongly associated with vascular rejection biopsies but was not an independent predictor of graft survival.